---
title: 'Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis
  (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial'
date: '2024-10-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39424560/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241019190408&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Fasudil is a small molecule inhibitor of Rho-associated
  kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In
  preclinical studies, fasudil has been shown to attenuate neurodegeneration, modulate
  neuroinflammation, and foster axonal regeneration. We aimed to investigate the safety,
  tolerability, and efficacy of fasudil in patients with amyotrophic lateral ...'
disable_comments: true
---
BACKGROUND: Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration, modulate neuroinflammation, and foster axonal regeneration. We aimed to investigate the safety, tolerability, and efficacy of fasudil in patients with amyotrophic lateral ...